BGPT: Author Review: Hakan Leblebicioglu

Explore by Goal

Quick Explanation Copied

Hakan Leblebicioglu — scientific strength review (skeptical, evidence-weighted)

Based on the works you provided, the author’s published footprint is concentrated in infectious diseases / infection control / travel-associated outbreaks, plus at least one study on Crimean-Congo hemorrhagic fever and broader synthesis pieces.

Strongest signal (from the provided papers list) is participation in large, data-heavy nosocomial infection control surveillance/reporting efforts, e.g. INICC-related publications ().

Long Explanation

Author Review: Hakan Leblebicioglu

Science-focused, skeptical, evidence-weighted critique based only on the papers/metadata you provided.

Scope note (important)

I do not know the author’s full CV, lab details, or complete publication list beyond what you supplied.
Some entries you provided appear to be reports/letters/reviews; scientific strength differs substantially by study type (e.g., meta-analyses vs. single-center retrospective cohorts vs. surveillance reporting).
Because external bibliographic sources (e.g., OpenAlex) were provided without a DOI, I only use DOI-indexable paper claims for evidence-backed statements, and I keep author-metric numbers as user-provided context (not as independently evidenced facts).

Evidence map (what the provided works suggest)

The works you listed emphasize: (1) hospital infection control / surveillance, (2) travel/migrant infectious disease risk framing, and (3) clinical epidemiology/synthesis for specific pathogens.

Nosocomial infection control surveillance: INICC-related publications ().
Resistance / microbial contamination: work on beta-lactamase detection in Gram-negative nosocomial pathogens and contaminated surfaces/objects in clinical settings (e.g., PER-1-type ESBLs: ; mobile-phone contamination evidence in clinical context: ).
Outbreak preparedness / regional reviews: disease burden and challenges for Crimean-Congo hemorrhagic fever and broader epidemic preparedness framing (e.g., ).
Clinical cohort comparison: retrospective single-center comparative analysis for CCHF in children vs. adults (from your list: — evidence-checking limited by missing DOI).

Publication-type robustness (how much to trust)

Different paper types answer different epistemic questions:

Type	Typical strengths	Main risks
Surveillance/report	Large-scale epidemiology across sites	Site heterogeneity, variable ascertainment, non-standardized definitions
Multicenter molecular studies	Assay-based pathogen characterization	Sampling bias in isolates; selection tied to clinical severity or referral patterns
Single-center retrospective cohorts	Hypothesis generation; pragmatic clinical comparisons	Confounding, missing data, selection bias
Reviews/letters	Breadth and synthesis; rapid communication	Selection bias, outdated evidence, lower causal strength

Deep critique on the strongest-evidence items from your provided list

1) INICC surveillance/report contributions (strength: scale; risk: cross-site comparability)

What’s strong: Large multi-country surveillance frameworks can reveal patterns that single-site studies miss, especially for device-associated modules and ICU infection control metrics ().
What to interrogate skeptically: If definitions, laboratory confirmation, and denominator data differ by site, apparent “global differences” can reflect measurement differences rather than biology. For rigorous inference, such papers should clearly describe case definitions, data cleaning, missingness handling, and how device- and procedure-associated categories are operationalized.
Why this matters for judging scientific strength: An author participating in surveillance reporting at scale likely has practical experience in epidemiologic data handling. But I cannot determine author-specific contribution quality (e.g., analysis vs. writing vs. data acquisition) from metadata alone.

2) Molecular epidemiology: PER-1-type beta-lactamases (strength: assay-linked mechanism; risk: isolate-selection bias)

What’s strong: Targeted detection and prevalence estimation of specific resistance elements in clinical isolates across multiple hospitals supports mechanistic interpretation about resistance dissemination ().
What to interrogate skeptically: Resistance prevalence estimates can be biased if hospitals preferentially submit harder-to-treat isolates or if sampling windows don’t reflect routine distributions. Rigorous studies address sampling strategy and include validation of genotyping assays.

3) Contamination of mobile phones (strength: direct measurement; risk: correlation ≠ transmission)

What’s strong: Measuring microbial contamination on objects used by healthcare workers is a direct observational assessment of a potential risk pathway ().
What to interrogate skeptically: Even if contamination is detected, concluding transmission impact requires either epidemiologic linkage (e.g., outbreak tracing) or intervention trials. Contamination presence does not by itself establish that contaminated phones cause infections.

Bias/limitations I cannot resolve with your provided snapshot

Attribution problem: Being a co-author on large surveillance reports doesn’t guarantee involvement in analysis; author contribution details are necessary for fair scoring.
Selection bias risk: Several infectious disease studies (especially retrospective cohorts and isolate collections) can be sensitive to clinical referral patterns and inclusion criteria.
Review/letter epistemic limitation: Reviews and letters can be valuable but do not carry the same evidentiary weight as prospective designs, well-controlled trials, or pre-registered analyses.
Missing DOI entries: For at least some items in your list, DOI metadata wasn’t provided, preventing evidence-grade critique of methods/results from those specific papers.

Practical scoring philosophy used here

Scientific strength is judged primarily by: (i) alignment of claims with study design, (ii) plausibility of causal inference given design limitations, (iii) evidence about measurement/assay/definitions, and (iv) reproducibility likelihood. Citation counts and h-index can indicate visibility, but they don’t directly measure rigor.

Overall evidence-weighted assessment (from provided works)

The strongest evidentiary signals in your list come from data-centric infection control surveillance and laboratory-linked microbiology/resistance measurement ( ; ; ).

What would most change the score

Full-text access to method details (definitions, inclusion criteria, missingness handling, lab validation).
Clarification of author-specific contributions (analysis vs. data collection vs. writing).
Whether key conclusions are supported by design-appropriate evidence (e.g., transmission claims supported by linkage, not mere contamination).

Feedback:

Updated: March 20, 2026